Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

Xenobiotica

Volumn 38, Issue 6, 2008, Pages 620-640

  Allan, G ^b   Davis, J ^a   Dickins, M ^b   Gardner, I ^a   Jenkins, T ^a   Jones, H ^b   Webster, R ^b   Westgate, H ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b NONE

Author keywords

Inter species scaling; Pharmacokinetics; Physiologically based pharmacokinetics (PBPK)

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; UK 453061; URIDINE DIPHOSPHATE GALACTOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; NONHUMAN; NORMAL HUMAN; PLASMA PROTEIN BINDING; RAT;

ANIMALS; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HALF-LIFE; HEPATOCYTES; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; NITRILES; PROTEIN BINDING; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS;

CANIS FAMILIARIS; RATTUS;

EID: 45849132066     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802069088     Document Type: Article

References (28)

1. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Advances in Drug Delivery Reviews 50(Suppl. 1):S41-S67.
2. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, Di Giambenedetto S, Narciso P, Ammassari A, Girardi E, et al. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Research and Human Retroviruses 18(12):835-838.
3. Boxenbaum H. 1980. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 8(2):165-176.
4. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicology and Industrial Health 13(4):407-484.
5. Carr A, Cooper DA. 2000. Adverse effects of antiretroviral therapy. Lancet 356(9239):1423-1430.
6. Corbau R, Allan G, Burt C, Fishburn L, Irving S, Knoechel T, Macdonald G, Martin A, Mowbray C, Mori J et al., 2007. UK-453,061: A non-nucleoside reverse transcriptase inhibitor for the treatment of drug-resistant HIV infections. Paper presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA, 17-20 September 2007.
7. Davis J, Jenkins T, Asken E, Stafford H, Hackman F, Weissgerber G. 2007. Pharmacokinetics of single and multiple oral doses of UK-453,061, a novel NNRTi, in healthy male subjects. Paper presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 22-25 July 2007.
8. De Buck SS, Sinha VK, Fenu LA, Nijsen M, Mackie C, Gilissen RAH. 2007. Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition 35:1766-1780.
9. Eagling VA, Back DJ, Barry MG. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology 44(2):190-194.
10. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16(4):569-577.
11. Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. 1995. Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 25(2):185-197.
12. Gobry VBG, Carrupt P-A, Testa B, Girault HH. 2000. Physicohcemical characterization of sildenafil: Ionization, lipophilicity behaviour, and ionic-partition diagram studied by two-phase titration and electrochemistry. Helvetica Chimica Acta 83:1465-1474.
13. Harris M, Montaner JS. 2000. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Reviews in Medical Virology 10(4):217-229.
14. Ito K, Houston JB. 2004. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharmaceutical Research 21(5):785-792.
15. Ito K, Houston JB. 2005. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmaceutical Research 22(1):103-112.
16. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clinical Pharmacokinetics 45(5):511-542.
17. Poulin P, Schoenlein K, Theil FP. 2001. Prediction of adipose tissue:Plasma partition coefficients for structurally unrelated drugs. Journal of Pharmaceutical Sciences 90(4):436-447.
18. Poulin P, Theil FP. 2000. A priori prediction of tissue-plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. Journal of Pharmaceutical Sciences 89(1):16-35.
19. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl MA, Pollard RB, Delapenha R, et al. 2003. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 349(24):2293-2303.
20. Rodgers T, Leahy D, Rowland M. 2005a. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. Journal of Pharmaceutical Sciences 94(6):1259-1276.
21. Rodgers T, Leahy D, Rowland M. 2005b. Tissue distribution of basic drugs: Accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. Journal of Pharmaceutical Sciences 94(6):1237-1248.
22. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. Journal of Pharmaceutical Sciences 95(6):1238-1257.
23. Smith PF, DiCenzo R, Morse GD. 2001. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clinical Pharmacokinetics 40(12):893-905.
24. Stopher D, McClean S. 1990. An improved method for the determination of distribution coefficients. Journal of Pharmacy and Pharmacology 42(2):144.
25. Torti C, Maggiolo F, Patroni A, Suter F, Ladisa N, Paraninfo G, Pierotti P, Orani AM, Minoli L, Arici C, et al. 2005. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: Results from the Italian MASTER Cohort. Journal of Antimicrobial Chemotherapy 56(1):190-195.
26. Turpin JA. 2003. The next generation of HIV/AIDS drugs: Novel and developmental antiHIV drugs and targets. Expert Review of Anti-Infective Therapy 1(1):97-128.
27. UNAIDS: AIDS epidemic update special report on HIV/AIDS. December 2006. ISBN: 929 173542 6.
28. Yu LX, Amidon GL. 1999. A compartmental absorption and transit model for estimating oral drug absorption. International Journal of Pharmaceutics 186(2):119-125.